medigraphic.com

2010, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (1)

Mexicanal physicians perception about hormonal therapy after the Women’s Health Initiative Study

Carranza-Lira S, Santos-González J

Language: Spanish
References: 18
Page: 61-66
PDF size: 35.81 Kb.


ABSTRACT

Background: The medical opinion after WHI study has changed. The aim was to know the opinion of Mexican physicians about hormone therapy (HT) after the WHI study.
Methods: there were given 14 questions to 463 physicians to know their opinion on HT according to risks, benefits, doses, indications and contraindications. Descriptive statistics were used for data analysis.
Results: Only 31 % begin HT after 60 years of age and 74 % considered that HT decreased osteoporosis risk; 73 % use progestin in women with uterus. 82 % did not believe that estrogen-progestin HT increased the possibility of endometrial cancer and 51 % believed that breast cancer possibility increased. The main indication for HT prescription was for bone loss diminution (51 %); 88 % considered that low dose HT was as effective as conventional dose.
Conclusions: the use of HT has been modified by Mexican physicians after the WHI study.


REFERENCES

  1. Stouthamer N, Visser AP, Oddens BJ, Beusmans G, Hoogland H, van Ree JW, et al. Dutch general practitioners’ attitudes towards the climacteric and its treatment. Eur J Obstet Gynecol Reprod Biol 1993;50(2):147-152.

  2. O’Connor V, Del Mar C, Sheehan M, Fox-Young S, Cragg C, Siskind V. The menopause and hormone replacement therapy: Australian general practitioners’ self reported opinions, attitudes and behaviour. Fam Pract 1996;13(5):421-426.

  3. Suárez-Almazor M, Homik JE, Messina D, Davis P. Attitudes and beliefs of family physicians and gynecologists in relation to the prevention and treatment of osteoporosis. J Bone Miner Res 1997;12 (7):1100-1107.

  4. Ena G, Rozenberg S. Issues to debate on the Women’s Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod 2003;18(11):2245-2248.

  5. Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gómez MS, et al. Patients’ and clini-cians’ attitudes after the Women’s Health Initiative study. Menopause 2004;11(1):57-61.

  6. Ismail HM, Aleveritis E, Guha B, Olive K, Sloan S. Attitudes toward hormone replacement therapy in the new millennium: university physicians’ and patients’ perspectives. J Invest Med 2005;53(6):305- 311.

  7. Nassar AH, Essamad HM, Awwad JT, Khoury NG, Usta IM. Gynecologists’ attitudes towards hormone therapy in the post “Women’s Health Initiative” study era. Maturitas 2005;52(1):18-25.

  8. Power ML, Zinberg S, Schulkin J. A survey of obstetricians-gynecologists concerning practice patterns and attitudes toward hormone therapy. Menopause 2006;13(3):434-441.

  9. Kang BM, Kim MR, Park HM, Yoon BK, Lee BS, Cheng HW, et al. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women’s Health initiative study. Menopause 2006; 13(1):125-129.

  10. Grodstein F, Stampfer MJ, Colditz GA, Willet WC, Manson JE, Joffe M, et al Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336(25):1769-1775.

  11. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330(15):1062-1071.

  12. Limouzin-Lamothe MA, Mairon N, Le Gal M. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994; 170(2):618-624.

  13. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case control study. Am J Epidemiol 1994;140(3):262-267.

  14. Colditz GA, Hankinson SE, Hunter DJ, Willet WC, Manson J, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24): 1589-1593.

  15. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348(19):1839-1854.

  16. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289(20):2651-2662.

  17. Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3): 321-333.

  18. Carranza-Lira S, Fragoso DJ. Percepción de los ginecoobstetras en relación con la terapia hormonal de reemplazo. Ginecol Obstet Mex 2007;75(2): 86-94.




2020     |     www.medigraphic.com